Difference between revisions of "Cervical cancer - null regimens"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "meet primary endpoints" to "meet co-primary endpoints") |
Warner-admin (talk | contribs) m (Text replacement - "_99|" to "_999|") |
||
| Line 20: | Line 20: | ||
|1986-1995 | |1986-1995 | ||
| style="background-color:#1a9851" |Phase 3 (C) | | style="background-color:#1a9851" |Phase 3 (C) | ||
| − | |[[# | + | |[[#BIP_999|BIP]] |
| style="background-color:#ffffbf" |Did not meet co-primary endpoints of ORR/OS | | style="background-color:#ffffbf" |Did not meet co-primary endpoints of ORR/OS | ||
|- | |- | ||
| Line 26: | Line 26: | ||
|1996-2001 | |1996-2001 | ||
| style="background-color:#1a9851" |Phase 3 (C) | | style="background-color:#1a9851" |Phase 3 (C) | ||
| − | |[[#Cisplatin_. | + | |[[#Cisplatin_.26_Vincristine_999|Cisplatin & Vincristine]] |
| style="background-color:#ffffbf" |Did not meet co-primary endpoints of PFS/OS | | style="background-color:#ffffbf" |Did not meet co-primary endpoints of PFS/OS | ||
|- | |- | ||
| Line 32: | Line 32: | ||
|2001-2005 | |2001-2005 | ||
| style="background-color:#1a9851" |Phase 3 (C) | | style="background-color:#1a9851" |Phase 3 (C) | ||
| − | |[[# | + | |[[#BOMP_999|BOMP]] |
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
|- | |- | ||
| Line 58: | Line 58: | ||
|2011-2017 | |2011-2017 | ||
| style="background-color:#1a9851" |Phase 3 (C) | | style="background-color:#1a9851" |Phase 3 (C) | ||
| − | |[[#Carboplatin_.26_Paclitaxel_.28CP. | + | |[[#Carboplatin_.26_Paclitaxel_.28CP.29_999|Carboplatin & Paclitaxel]] |
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
|- | |- | ||
| Line 64: | Line 64: | ||
|2015-2017 | |2015-2017 | ||
| style="background-color:#1a9851" |Phase 3 (C) | | style="background-color:#1a9851" |Phase 3 (C) | ||
| − | |[[#Carboplatin_.26_Paclitaxel_.28CP. | + | |[[#Carboplatin_.26_Paclitaxel_.28CP.29_999|Carboplatin & Paclitaxel]] |
| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | ||
|- | |- | ||
Revision as of 12:22, 18 June 2023
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main cervical cancer page for current regimens.
Neoadjuvant therapy
No neoadjuvant therapy
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Herod et al. 2000 | 1986-1995 | Phase 3 (C) | BIP | Did not meet co-primary endpoints of ORR/OS |
| Eddy et al. 2007 (GOG 141) | 1996-2001 | Phase 3 (C) | Cisplatin & Vincristine | Did not meet co-primary endpoints of PFS/OS |
| Katsumata et al. 2013 (JCOG 0102) | 2001-2005 | Phase 3 (C) | BOMP | Did not meet primary endpoint of OS |
No systemic therapy prior to surgery.
Subsequent treatment
References
- Herod J, Burton A, Buxton J, Tobias J, Luesley D, Jordan S, Dunn J, Poole CJ. A randomised, prospective, phase III clinical trial of primary bleomycin, ifosfamide and cisplatin (BIP) chemotherapy followed by radiotherapy versus radiotherapy alone in inoperable cancer of the cervix. Ann Oncol. 2000 Sep;11(9):1175-81. link to original article PubMed
- GOG 141: Eddy GL, Bundy BN, Creasman WT, Spirtos NM, Mannel RS, Hannigan E, O'Connor D. Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the Gynecologic Oncology Group. Gynecol Oncol. 2007 Aug;106(2):362-9. Epub 2007 May 9. link to original article PubMed
- JCOG 0102: Katsumata N, Yoshikawa H, Kobayashi H, Saito T, Kuzuya K, Nakanishi T, Yasugi T, Yaegashi N, Yokota H, Kodama S, Mizunoe T, Hiura M, Kasamatsu T, Shibata T, Kamura T; JCOG. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer. 2013 May 28;108(10):1957-63. Epub 2013 May 2. link to original article link to PMC article PubMed Clinical Trial Registry
Adjuvant therapy
Observation
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Awaiting publication (OUTBACK) | 2011-2017 | Phase 3 (C) | Carboplatin & Paclitaxel | Did not meet primary endpoint of OS |
| Tangjitgamol et al. 2019 (ACTLACC) | 2015-2017 | Phase 3 (C) | Carboplatin & Paclitaxel | Did not meet primary endpoint of PFS |
No further treatment after definitive therapy.
Preceding treatment
References
- ACTLACC: Tangjitgamol S, Tharavichitkul E, Tovanabutra C, Rongsriyam K, Asakij T, Paengchit K, Sukhaboon J, Penpattanagul S, Kridakara A, Hanprasertpong J, Chomprasert K, Wanglikitkoon S, Atjimakul T, Pariyawateekul P, Katanyoo K, Tanprasert P, Janweerachai W, Sangthawan D, Khunnarong J, Chottetanaprasith T, Supawattanabodee B, Lertsanguansinchai P, Srisomboon J, Isaranuwatchai W, Lorvidhaya V. A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial. J Gynecol Oncol. 2019 Jul;30(4):e82. Epub 2019 Apr 10. link to original article link to PMC article PubMed Clinical Trial Registry
- OUTBACK: ACTRN12610000732088